- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Hypertension Medication Caused Rare Case of Severe Neutropenia in Patient
In an unusual case, a patient was diagnosed with febrile neutropenia after starting benazepril, an angiotensin-converting enzyme inhibitor. The treatment is rarely associated with agranulocytosis, which is defined as severe neutropenia.
In an unusual case, a patient was diagnosed with febrile neutropenia after starting benazepril, an angiotensin-converting enzyme inhibitor. The treatment is rarely associated with agranulocytosis, which is defined as severe neutropenia.
The case was published in the American Journal of Case Reports by researchers with the Bronx Lebanon Hospital Center.
While the incidence of drug-induced agranulocytosis (DIAG) has remained stable, the condition is likely underreported, according to the authors. “The detailed pathological mechanism of DIAG is poorly understood and a causal relationship between the condition and a drug can be difficult to elicit,” they wrote.
The patient in question was admitted to the emergency department with throat pain and difficulty swallowing. The patient had a white blood cell count of 0.5 K/μL with absolute neutrophilic count of zero. Hemoglobin level and platelet count were both normal.
Once the treating physicians were able to conclude benazepril, which had been prescribed to the patient 2 months prior, was the culprit causing agranulocytosis, it was discontinued as a medication.
“This resulted in fast recovery of the white blood cell count,” the authors wrote. “The patient remained afebrile for one week and was discharged with a diagnosis of benazepril-induced agranulocytosis.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
